Yassin Abdel Ghaffar Charity Center for Liver Disease and Research Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2009
NCT02027493
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Professor Yassin Abdel Ghaffar Charity Center for Liver Disease and Research | Yassin Abdel Ghaffar Charity Center for Liver Disease and Research | Yassin Abdel Ghaffar Charity Center for Liver Disease and Research, 2851 Cairo, Egypt

Active Ingredients

Drugs in Phase 4 Trials (2)

ledipasvir (Harvoni) (1 trial)

sofosbuvir (sovaldi) (2 trials)

Drugs in Phase 3 Trials (1)

daclatasvir (daklinza) (1 trial)

Drugs in Other Trials (2)

interferon alpha-2a (roferon-a) (1 trial)

ribavirin (virazole) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5